Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
AssigneeThe USA, as represented by the Secretary, Dept. of Health and Human Services
InventorsDeb K. Chatterjee, Stanislaw J. Kaczmarczyk
Life of this patent
Estimating the term…
Abstract
Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.
Claims10
A pharmaceutical composition comprising a virus like particle (VLP), the VLP comprising:
- a. an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises:
- (i) a sequence encoding both subunits of a human class II major histocompatibility (MHC) antigen, and
- (ii) a sequence encoding a costimulatory signal protein selected from the group consisting of CD80, CD28, CD86, and CTLA-4;
- b. a retroviral gag protein, and
- c. a fusogenic envelope protein,
- wherein the VLP does not contain an alphavirus structural protein gene, wherein the VLP is not cytopathic to a eukaryotic cell.
Dependencies are inferred from the claim text.